Amgen: Clinical Trials

566 trials sponsored by Amgen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

367 completed, 88 terminated, 35 active not recruiting, 26 withdrawn. 566 Phase 2, 88 Phase 1, 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2566Completed 367, Terminated 88, Active not recruiting 35, Withdrawn 26, Recruiting 24, Unknown 20, Not yet recruiting 4, Enrolling by invitation 1, Suspended 1
Phase 188Completed 47, Terminated 17, Active not recruiting 8, Withdrawn 7, Recruiting 4, Unknown 4, Not yet recruiting 1
Phase 314Completed 8, Terminated 4, Active not recruiting 1, Recruiting 1

Follow Amgen: new trials by email

Trials (filtered) newest first · largest first

All 566 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-01-272026-10-07
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingUniversity of Alberta802027-01-022026-08-12
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
Inebilizumab - Immunoglobulin G4-related Disease
Phase 2RecruitingAmgen152026-10-212026-11-16
LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
Xaluritamig - Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer
Phase 2Not yet recruitingThomas Jefferson University302026-10-012026-08-14
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Inebilizumab - Generalized Myasthenia Gravis
Phase 2RecruitingAmgen152026-07-212026-10-23
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab - Osteoporosis, Post-menopausal
Phase 2WithdrawnUniversity of Pittsburgh2026-06-202026-06-04
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's
Phase 2 / Phase 3RecruitingRobert Spiera, MD302026-05-222026-09-02
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
AMG 732 - Thyroid Eye Disease
Phase 2RecruitingAmgen302026-05-072026-07-23
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Blinatumomab - Phase 2 Study, Blinatumomab
Phase 2Active not recruitingM.D. Anderson Cancer Center402026-04-212026-11-12
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Tarlatamab - Extensive Stage Lung Small Cell Cancer
Phase 2RecruitingETOP IBCSG Partners Foundation482026-04-152026-09-21
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma
Phase 2RecruitingAsrar Alahmadi392026-03-202026-07-06
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Maridebart cafraglutide, Placebo - Overweight or Obesity and Elevated Liver Fat
Phase 2Active not recruitingAmgen1802026-03-052026-09-28
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32026-01-302026-08-18
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Subcutaneous Blinatumomab - CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Phase 2RecruitingWest Virginia University782026-01-152026-04-13
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Sotorasib, Panitumumab - Advanced Solid Tumors
Phase 2RecruitingAmgen142026-01-022026-07-23
Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
Tarlatamab - Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
Phase 2RecruitingNational Taiwan University Hospital322026-01-012026-09-17
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Tarlatamab, standard of care second-line chemotherapy (FOLFIRI) - Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
Phase 2TerminatedGrupo Espanol de Tumores Neuroendocrinos12025-12-182026-09-18
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingAmgen1042025-12-082026-10-05
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Tarlatamab, Temozolomide (TMZ) - Glioma, CNS Tumor, Adult
Phase 1 / Phase 2RecruitingCentre Leon Berard702025-11-042026-09-14

Showing 20 of 566. Sign in to see all of them.

Conditions studied

Multiple Myeloma (52)  ·  Neoplasms (44)  ·  Colorectal Neoplasms (38)  ·  Breast Neoplasms (34)  ·  Carcinoma, Non-Small-Cell Lung (31)  ·  Neoplasm Metastasis (26)  ·  Anemia (19)  ·  Recurrence (18)  ·  Arthritis, Rheumatoid (16)  ·  Colonic Neoplasms (16)  ·  Lymphoma, Non-Hodgkin (16)  ·  Lung Neoplasms (15)  ·  Lymphoma (15)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (15)  ·  Rectal Neoplasms (14)

Interventions

Panitumumab (74)  ·  carfilzomib (42)  ·  Dexamethasone (41)  ·  Denosumab (33)  ·  blinatumomab (31)  ·  pegfilgrastim (27)  ·  Darbepoetin alfa (24)  ·  Carboplatin (23)  ·  Paclitaxel (23)  ·  Cisplatin (21)  ·  Cyclophosphamide (20)  ·  romiplostim (20)  ·  Fluorouracil (19)  ·  Irinotecan (19)  ·  Lenalidomide (18)

Countries

United States (313)  ·  Spain (85)  ·  Germany (81)  ·  Canada (80)  ·  France (78)  ·  Poland (60)  ·  United Kingdom (56)  ·  Italy (55)  ·  Australia (51)  ·  Belgium (48)  ·  Netherlands (46)  ·  Czechia (38)  ·  Japan (36)  ·  Greece (34)  ·  Denmark (33)

Top investigators

John Rieth, MD (3)  ·  Antonio Arrivi, MD (2)  ·  Aram Hezel, MD (2)  ·  Benjamin Derman, MD (2)  ·  Elias Jabbour, MD (2)  ·  Elizabeth Shane, MD (2)  ·  Heinz Ludwig, MD (2)  ·  Jaime Feliu, MD (2)  ·  James R Berenson, MD (2)  ·  Joan Maurel, MD (2)

Results publications

PMID 41671463, PMID 24144944, PMID 34928306, PMID 37316690, PMID 20838998, PMID 22070868, PMID 22961727, PMID 23986513, PMID 24014831, PMID 27789188, PMID 32079690, PMID 33051459, PMID 34213592, PMID 34301173, PMID 35314069, PMID 35820631, PMID 37491104, PMID 38979716, PMID 39097160, PMID 40780143, PMID 12481149, PMID 12675312, PMID 12957457, PMID 13680158, PMID 14770445, PMID 15173079, PMID 15210739, PMID 15352656, PMID 15522938, PMID 15860486, PMID 15909591, PMID 15911237, PMID 15983958, PMID 16200343, PMID 16381629, PMID 16411031, PMID 16495394, PMID 16530701, PMID 16786120, PMID 16899365, PMID 17289537, PMID 17602062, PMID 17664336, PMID 17671985, PMID 17699221, PMID 17705175, PMID 17708711, PMID 17785764, PMID 17962619, PMID 18195176

NIH funding

2014 (9), 2016 (9), 2023 (9), 2017 (8), 2019 (7), 2008 (5), 2009 (5), 2015 (5), 2018 (3), 2025 (3), M01RR001032 (2), R01DK058785 (2), 1UF1AG046150-01 (1), 2004 (1), 2005 (1)